Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer

被引:1
|
作者
Peters, Gabrielle W. [1 ]
Talcott, Wesley [1 ]
Peters, Nicholas V. [2 ]
Dhanasopan, Andrew [3 ]
Lacy, Jill [4 ]
Cecchini, Michael [4 ]
Kortmansky, Jeremy [4 ]
Stein, Stacey [4 ]
Lattanzi, Stephen [4 ]
Park, Henry S. [1 ]
Boffa, Daniel [3 ]
Johung, Kimberly L. [1 ]
Jethwa, Krishan R. [5 ]
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT USA
[2] Yale Univ, Dept Gen Surg, Sch Med, New Haven, CT USA
[3] Yale Univ, Dept Thorac Surg, Sch Med, New Haven, CT USA
[4] Yale Univ, Dept Med Oncol, Sch Med, New Haven, CT USA
[5] Mayo Clin, Radiat Oncol, Rochester, MN USA
关键词
Induction chemotherapy; esophageal cancer; gastroesophageal cancer; PHASE-II TRIAL; NEOADJUVANT CHEMORADIOTHERAPY; TREATMENT TIME; PLUS SURGERY; THERAPY; SURVIVAL; IMPACT;
D O I
10.21037/jgo-22-1005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: For patients with operable locally advanced esophageal carcinoma (LA-EC), we hypothesized that pre-operative induction chemotherapy followed by chemoradiotherapy (IC-CRT) would improve progression-free survival (PFS) and overall survival (OS) when compared to chemoradiotherapy (CRT). Methods: This was a single institution retrospective cohort study including patients with LA-EC who received preoperative-intent IC-CRT vs. CRT between 2013-2019. The Kaplan-Meier method was used to estimate OS and PFS. Cox proportional hazards regression was used to assess for variables associated with survival. The impact of treatment group on pathologic response was assessed by chi-square. Results: Ninty-five patients were included for analysis (IC-CRT n=59; CRT n=36) and the median followup was 37.7 months (IQR: 16.8-56.1). There was no difference in median PFS or OS for IC-CRT or CRT, 22 months (95% CI: 12-59) vs. 32 months (95% CI: 10-57) (P=0.64) and 39 months ( 95% CI: 23-not reached) vs. 56.5 months (95% CI: 38-not reached) (P=0.36), respectively. Amongst the subset of patients with adenocarcinoma histology, there was no difference in median PFS or OS, nor was there when analyses were further restricted to those who received >= 3 cycles of induction 5-fluorouracil and platinum, or for those who underwent esophagectomy. Pathologic complete response occurred in 45% vs. 29% (P=0.24) and N-stage regression occurred in 72% vs. 58% (P= 0.28) of patients in the IC- CRT and CRT cohorts, respectively. Distant metastasis occurred in 44% of patients in each treatment cohort. Conclusions: For patients with LA-EC, preoperative-intent IC-CRT was not associated with improved PFS or OS when compared with CRT.
引用
收藏
页码:1181 / +
页数:16
相关论文
共 50 条
  • [1] Induction Chemotherapy for Locally Advanced Esophageal Cancer
    Harada, Guilherme
    da Cunha Colombo Bonadio, Renata Rodrigues
    Cordeiro de Araujo, Frederico Cantarino
    Victor, Carolina Ribeiro
    Aissar Sallum, Rubens Antonio
    Ribeiro Junior, Ulysses
    Cecconello, Ivan
    Takeda, Flavio Roberto
    de Castria, Tiago Biachi
    JOURNAL OF GASTROINTESTINAL CANCER, 2020, 51 (02) : 498 - 505
  • [2] Induction Chemotherapy for Locally Advanced Esophageal Cancer
    Guilherme Harada
    Renata Rodrigues da Cunha Colombo Bonadio
    Frederico Cantarino Cordeiro de Araújo
    Carolina Ribeiro Victor
    Rubens Antonio Aissar Sallum
    Ulysses Ribeiro Junior
    Ivan Cecconello
    Flávio Roberto Takeda
    Tiago Biachi de Castria
    Journal of Gastrointestinal Cancer, 2020, 51 : 498 - 505
  • [3] Oxaliplatin-containing adjuvant chemotherapy improves the survival of locally advanced rectal cancer patients with pathological complete response after pre-operative chemoradiotherapy
    Peng, Jian-Hong
    Lin, Jun-Zhong
    Rong, Yu-Ming
    Zhu, Ying
    Deng, Yu-Xiang
    Zhao, Yu-Jie
    Lu, Zhen-Hai
    Wu, Xiao-Jun
    Pan, Zhi-Zhong
    GASTROENTEROLOGY REPORT, 2018, 6 (03): : 195 - 201
  • [4] Pre-operative radiochemotherapy with raltitrexed for resectable locally-advanced rectal cancer: A phase II study
    Leonardi, Maria Cristina
    Zampino, Maria Giulia
    Luca, Fabrizio
    Jereczek-Fossa, Barbara Alicja
    Petazzi, Elena
    Tatani, Brunilda
    Lazzari, Roberta
    Biffi, Roberto
    Lorizzo, Katia
    Magni, Elena
    Scanniffio, Diego
    Orsi, Franco
    Bonomo, Guido
    Petralia, Giuseppe
    Trovato, Cristina
    Crosta, Cristiano
    Andreoni, Bruno
    Orecchia, Roberto
    ANTICANCER RESEARCH, 2006, 26 (3B) : 2419 - 2423
  • [5] Triple Induction Chemotherapy and Chemoradiotherapy for Locally Advanced Esophageal Cancer. A Phase II Study
    Eisterer, Wolfgang
    De Vries, Alexander
    Kendler, Dorota
    Spechtenhauser, Bernhard
    Koenigsrainer, Alfred
    Nehoda, Hermann
    Virgolini, Irene
    Lukas, Peter
    Bechter, Oliver
    Woell, Ewald
    Oefner, Dietmar
    ANTICANCER RESEARCH, 2011, 31 (12) : 4407 - 4412
  • [6] Neoadjuvant chemoradiotherapy or chemotherapy for locally advanced esophageal cancer?
    Babic, B.
    Fuchs, H. F.
    Bruns, C. J.
    CHIRURG, 2020, 91 (05): : 379 - 383
  • [7] Neoadjuvant Chemotherapy or Chemoradiotherapy for Locally Advanced Esophageal Cancer
    Smithers, B. Mark
    Thomson, Iain
    THORACIC SURGERY CLINICS, 2013, 23 (04) : 509 - +
  • [8] Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer
    Hashimoto, Masashi
    Shirakawa, Yasuhiro
    Maeda, Naoaki
    Tanabe, Shunsuke
    Noma, Kazuhiro
    Sakurama, Kazufumi
    Katsui, Kuniaki
    Nishizaki, Masahiko
    Fujiwara, Toshiyoshi
    ESOPHAGUS, 2020, 17 (02) : 127 - 134
  • [9] Patterns of failure in patients with locally advanced rectal cancer receiving pre-operative or post-operative chemoradiotherapy
    Yeo, Seung-Gu
    Kim, Min-Jeong
    Kim, Dae Yong
    Chang, Hee Jin
    Kim, Min Ju
    Baek, Ji Yeon
    Kim, Sun Young
    Kim, Tae Hyun
    Park, Ji Won
    Oh, Jae Hwan
    RADIATION ONCOLOGY, 2013, 8
  • [10] Chemoradiotherapy with or without Induction Chemotherapy for Locally Advanced Pancreatic Cancer: a UK Multi-institutional Experience
    Gillmore, R.
    Laurence, V.
    Raouf, S.
    Tobias, J.
    Blackman, G.
    Meyer, T.
    Goodchild, K.
    Collis, C.
    Bridgewater, J.
    CLINICAL ONCOLOGY, 2010, 22 (07) : 564 - 569